Table 3 summarizes the main features of cancer cell, CD8+ T cell, and FoxP3+ T cell density spatial distributions presented in Fig 5, where all contour plots represent cell densities ten months after the initial diameter condition is met and 3 mg/kg nivolumab is administered every two weeks. This evidence concerns the gene CD8A and cancer.